Ipamorelin + CJC-1295: The Growth Hormone Peptide Stack

The ipamorelin and CJC-1295 combination is the most widely used growth hormone peptide stack — and the pharmacological rationale is sound. These two peptides work through completely independent receptor systems to stimulate GH release. Ipamorelin activates the ghrelin receptor (GHSR-1a) on pituitary somatotrophs. CJC-1295 activates the GHRH receptor (GHRH-R) on those same cells. When both receptors are activated simultaneously, the resulting GH pulse is significantly larger than either peptide produces alone — an additive to synergistic effect that is well-documented in preclinical data.

The Two-Pathway Model

Growth hormone release from the pituitary is regulated by two primary hormones:

GHRH (Growth Hormone Releasing Hormone): Released from the hypothalamus, it binds GHRH-R on pituitary somatotrophs and stimulates GH secretion. CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that extends its half-life from minutes (native GHRH) to approximately 7 days.

Ghrelin: Released from the stomach and hypothalamus, it binds GHSR-1a and independently stimulates GH release. It also sensitizes somatotrophs to GHRH, which is why combining the two pathways is synergistic. Ipamorelin is a synthetic ghrelin receptor agonist.

Additionally, somatostatin (from the hypothalamus) suppresses GH release. The GHRH and ghrelin pathways both inhibit somatostatin tone, which further amplifies GH release when both are active simultaneously.

CJC-1295: Two Versions

There are two distinct molecules sold as CJC-1295:

CJC-1295 with DAC (true CJC-1295): The DAC (Drug Affinity Complex) modification causes the peptide to covalently bind to albumin in the bloodstream, extending half-life to 7–8 days. This creates a persistent elevation in baseline GH levels rather than discrete pulses. Dosed once or twice per week.

CJC-1295 without DAC (also called Mod GRF 1-29): Lacks the DAC modification. Has a half-life of 30–60 minutes. Creates a GH pulse when injected, similar to native GHRH. Must be dosed multiple times daily. This version is preferred when trying to mimic natural pulsatile GH release.

For the ipamorelin stack, CJC-1295 without DAC (Mod GRF 1-29) is generally preferred because it creates synchronized pulses with ipamorelin rather than a blunted sustained elevation.

Dosage Protocol

Standard pulse protocol (most common):

• Ipamorelin: 200–300 mcg subcutaneously
• CJC-1295 without DAC (Mod GRF 1-29): 100–200 mcg subcutaneously
• Inject both simultaneously or within minutes of each other
• 1–3 times daily; the pre-sleep dose is most critical

Timing:

• Best: 30–60 minutes before sleep, on an empty stomach
• Second dose: upon waking (before breakfast)
• Third dose: 30 minutes pre-workout

The empty stomach requirement is important: elevated insulin blunts GH release through somatostatin stimulation. Injecting while insulin is elevated reduces effectiveness.

With CJC-1295 with DAC:

• CJC-1295 with DAC: 1–2 mg subcutaneously once per week
• Ipamorelin: 200–300 mcg subcutaneously 1–3 times daily
• This combination creates a sustained GH elevation with superimposed ipamorelin pulses

Expected Effects

The ipamorelin/CJC-1295 stack produces the downstream effects of elevated GH:

IGF-1 elevation: GH drives hepatic IGF-1 production, which mediates many of GH's anabolic and tissue-repair effects. IGF-1 levels typically rise 30–50% above baseline within 4–8 weeks on this stack.

Body composition: Gradual reduction in visceral fat (GH is directly lipolytic), gradual increase in lean mass, and improved muscle fullness over 8–12+ weeks.

Recovery: Reduced muscle soreness, faster recovery from training, and improved tissue repair.

Sleep quality: Enhanced slow-wave sleep depth, contributing to the natural GH pulse that occurs during sleep.

Skin and collagen: GH and IGF-1 stimulate collagen synthesis, leading to improved skin elasticity and joint health over time.

Cycle Recommendations

Beginner (6-month cycle):

• Months 1–6: nightly ipamorelin 200 mcg + Mod GRF 1-29 100 mcg before sleep
• 1-month break
• Retest IGF-1

Intermediate (ongoing protocol):

• Ipamorelin 300 mcg + Mod GRF 1-29 200 mcg 2x daily (sleep + morning)
• 5 days on / 2 days off, or continuous cycling

Safety Considerations

The key safety consideration with any GH-elevating protocol is the theoretical concern about stimulating growth of pre-existing occult tumors — since GH and IGF-1 are anabolic hormones. Individuals with a personal or family history of cancer should consult a physician before use. Water retention, carpal tunnel syndrome, and insulin resistance can occur with significant GH elevation.

FAQ

How is this stack different from injecting HGH directly? Exogenous HGH suppresses endogenous production via negative feedback on the pituitary and hypothalamus, leading to pituitary atrophy over time. The ipamorelin/CJC-1295 stack stimulates the pituitary's own GH production, preserving the natural feedback axis and pulsatile release pattern.

How long before I see results? Subjective sleep improvement is often noted in weeks 1–2. Body composition changes typically become noticeable at weeks 6–10. Full effects develop over 3–6 months of consistent use.

Should I take anything else with this stack? Ensuring adequate sleep, low stress, and low insulin at injection time maximizes GH pulse amplitude. Some practitioners add thyroid support (T4/T3 monitoring) since GH affects thyroid hormone conversion.

Related Articles

• Growth Hormone Peptides: Complete Guide to GH Secretagogues
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.